

Publikationen 1998

Originalpublikationen in wissenschaftlichen Zeitschriften

1. Bernasconi E, Ruef C. Strategien zur Optimierung des Antibiotikaeinsatzes im Spital. *Swiss-NOSO* 1998; 5: 17-20.
2. Bisset LR, Cone RW, Huber W, Battegay M, Vernazza PL, Weber R, Grob PJ, Opravil M and the Swiss HIV Cohort Study. Highly active anti-retroviral therapy during early HIV-infection reverses T-cell activation and maturation abnormalities. *AIDS* 1998; 12: 2115-2123.
3. Cone RW, Gowland P, Opravil M, Grob P, Ledergerber B and the Swiss HIV Cohort Study. Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infection. *AIDS* 1998; 12: 2253-2260.
4. Deplazes P, Mathis A, van Saanen M, Iten A, Keller R, Tanner I, Glauser M, Weber R, Canning EU. Double infection with *Vittaforma corneae* and *Encephalitozoon hellem* in an AIDS patient. *Clin Infect Dis* 1998; 27: 1521-4.
5. Egger M, Sudre P, Battegay M, Wirz M, Rickenbach M, Ledergerber B. Impact des nouvelles associations thérapeutiques sur l'incidence du Sida dans l'étude suisse de cohorte VIH. *Med et Hyg* 1998; 56: 1382-1386.
6. Eich-Höchli D, Niklowitz NW, Clement U, Lüthy R, Opravil M. Predictors of unprotected sexual contacts in HIV-infected persons in Switzerland. *Arch Sexual Behavior* 1998; 27: 77-90.
7. Eriksson U, Opravil M, Amann FW, Schaffner A. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? [letter] *AIDS* 1998; 12: 2079-2080.
8. Fleisch F, Burnens A, Weber R, Zbinden R. *Helicobacter* sp. strain Mainz isolated from cultures of blood from two patients with AIDS. *Clin Infect Dis* 1998; 26: 526-527.
9. Flepp M, Levi G. Contrasts in managing opportunistic infections in HIV disease between Europe and South America. *Int J Clin Practice* 1998 (Suppl 95) 54.
10. Flepp M. HIV und Internet – eine unvollständige Übersicht. *infomed-screen* 1998;2:64.
11. Flepp M. HIV-Postexpositionsprophylaxe – Grenzen und Möglichkeiten. *Jahresbericht der Zürcher AIDS-Hilfe 1997*. Zürich 1998.
12. Friedl A, Schaad HJ, Sturzenegger M, Caversaccio M. Otogene Meningitis. *Schweiz Rundsch Med Prax.* 1998; 87:839-844
13. Fuchs KP, Ruef C, Weber R. Antibiotikagebrauch und Resistenz: auch ein Problem in der ambulanten Praxis? (Teil 2). *Schweiz. Aerztezeitung* 1998; 79:2401-2402.

14. Hofer M, Joller HI, Grob PJ, Lüthy R, Opravil M, and the Swiss HIV Cohort Study: Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. *Eur J Clin Microbiol Infect Dis* 1998; 17: 6-13.
15. Huber W, Haji H, Charlwood J.D, Kitua A, Certa U, Walliker D, Tanner M. Genetic characterization of the malaria parasite *Plasmodium falciparum* in the transmission from the host to the vector. *Parasitology* 1998; 116: 95-101.
16. Jost J, Colombo C, Maziéro A, Ledergerber B, Francioli P. Berufliche bedingte Blut-Expositionen und medikamentöse HIV-Postexpositionsprophylaxe (PEP) in der Schweiz bis Ende 1996. *BAG Bull* 1998; No. 27: 14-19.
17. Jost J, Flepp M, Vernazza P, Battegay M, Kaiser L, Weber R, Bernasconi E, für die Subkommission Klinik (SKK) der eidgenössischen Kommission für Aidsfragen (EKAF). Antiretrovirale HIV-Therapie: Empfehlungen 1998. *Bulletin des Bundesamtes für Gesundheit* 1998; 44: 5-9.
18. Jost J, Flepp M, Vernazza P, Battegay M, Kaiser L, Weber R, Bernasconi E. Antiretrovirale HIV-Therapie. Empfehlungen 1998. *BAG Bull* 1998; No. 44: 5-9.
19. Jost J, Weber R. Gerechtfertigter oder ungerechtfertigter Einsatz von Antibiotika: wo liegen die Grenzen? (Teil 3). *Schweiz. Aerztezeitung* 1998; 79: 2506-2507.
20. Jost J. HIV-Postexpositionsprophylaxe inner- und ausserhalb des Spitals. *Ther Umschau* 1998; 55: 289 - 294.
21. Knuchel MC, Spira TJ, Neumann AU, Xiao L, Rudolph DL, Phair J, Wolinsky SM, Koup RA, Cohen OJ, Folks TM, Lal RB. Analysis of a biallelic polymorphism in the tumor necrosis factor alpha promoter and HIV type 1 disease progression. *AIDS Res Hum Retroviruses* 1998; 14: 305-309.
22. Ledergerber B, Egger M, Rickenbach M, Weber R, and the Swiss HIV Cohort Study. Poverty and prognosis of HIV infection in Switzerland. [letter] *AIDS* 1998;12: 1933-1934.
23. Lipp HP, Stagliar Bozicevic M, Fischer M, Wolfer DP. A 2-year longitudinal study of swimming navigation in mice devoid of the prion protein: no evidence for neurological anomalies or spatial learning impairments. *Behavioural Brain Research* 1998; 95: 47-54.
24. Luthi J-C, Dubois-Arber F, Iten A, Maziéro A, Colombo C, Jost J, Francioli P. The occurrence of percutaneous injuries to health care workers: a cross sectional survey in seven Swiss hospitals. *Schweiz Med Wochenschr* 1998;128: 536-543.
25. Müller V, Opravil M. Langjährige HIV-Infektion und dialysepflichtige Niereninsuffizienz bei Analgetikanephropathie. *Ther Umschau* 1998; 55: 555-557.

26. Opravil M, Hill AM, DeMasi R, Dawson D. Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine. *Antiviral Therapy* 1998; 3: 169-176.
27. Opravil M, Hunziker R, Lüthy R, Grob PJ und die Schweizerische HIVKohortenstudie (SHCS). Chronische Hepatitis B und C bei HIV-infizierten Patienten. *DMW* 1998; 123: 753-760.
28. Opravil M, Rickenbach M, Ledergerber B für die Schweizerische HIVKohortenstudie. Die Schweizerische HIV-Kohortenstudie – Verbindung zwischen klinischer Forschung und ärztlicher Praxis. *Ther Umschau* 1998; 55:329-334.
29. Opravil M. Can prophylaxis for opportunistic infections be discontinued in the era of highly-active antiretroviral therapy? *Practical issues in HIV and AIDS Patient Management* 1998; issue 19: 3-8.
30. Opravil M. Editorial. 12. Welt-AIDS-Kongress. *Kolloquium Medical Tribune* 1998; Suppl. 41: 4.
31. Peghini PA, Zahner R, Kuster H, Schott H, Schwendener RA. In vitro antihuman immuno-deficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of hetero-dinucleoside phosphates containing AZT or ddC. *Antiviral Chem Chemother.* 1998; 9: 117-126.
32. Pittet D, Harbarth S, Francioli P, Ruef C, Widmer AF. Infections nosocomiales dans les services de chirurgie d'hôpitaux universitaires helvétiques. *Méd et Hyg* 1998;56: 1853-1856.
33. Pusterla N, Weber R, Wolfensberger C, Schär G, Zbinden R, Fierz W, Madigan JE, Dumler JS, Lutz H. Serological evidence of human granulocytic ehrlichiosis in Switzerland. *Eur J Clin Microbiol Infect Dis* 1998; 17: 207-209.
34. Rinder H, Janitschke K, Aspöck H, da Silva AJ, Deplazes P, Fedorko DP, Franzen C, Heise W, Hüniger F, Lehmacher A, Meyer C, Molina JM, Weber R, Löscher T. A blinded, externally controlled multi-center evaluation for the detection of microsporidia by light microscopy and PCR. *J Clin Microbiol* 1998; 36:1814-1818.
35. Rohner P, Jahn EIM, Ninet B, Ionati C, Weber R, Auckenthaler R, GE Pfyffer. Rapid diagnosis of pulmonary tuberculosis with the Lcx Mycobacterium tuberculosis Assay and comparison with conventional diagnostic techniques. *J Clin Microbiol* 1998; 36: 3051-3054.
36. Rothen M, Bisset LR, Joller-Jemelka HI, Grob P, Lüthy R, Opravil M. Improvement in immune function due to treatment with indinavir despite severe immune deficiency. *Antiviral Therapy* 1998; 3: 159-167.
37. Ruef C, Francioli P. Qualitätssicherung im Spital (IV) - Ergebnisqualität und Spitalhygiene. *Swiss-NOSO* 1998; 5: 3-6.
38. Ruef C, Pagano E, Raeber PA, Gaia V, Peduzzi R. Legionellen im Spital - Praktische Hinweise für das Screening. *Swiss-NOSO* 1998; 5: 12-14.

39. Ruef C, Pittet D. Epidemiologie et prévention des infections du site chirurgical: progrès et problèmes. *Méd et Hyg* 1998; 56: 1846-1852.
40. Ruef C, Pittet D. Nosokomiale Bakteriämien (Teil 1) *Swiss-NOSO* 1998; 5: 9-12.
41. Ruef C, Pittet D. Nosokomiale Bakteriämien (Teil 2). *Swiss-NOSO* 1998; 5: 22-23.
42. Ruef C, Zbinden R. (1998) Antibiotika und Resistenzentwicklung: ein ökologisches Problem? (Teil 4). *Schweizerische Aerztezeitung* 1198; 79:2623-2625.
43. Ruef C. Isolierungs- und Vorsichtsmassnahmen zur Prävention von Infektionskrankheiten im Spital. *Tribuna Medica Ticinese*. 1998; 63: 26-29.
44. Ruef C. Nosocomial Legionnaires' disease - strategies for prevention. *J Microbiol Methods* 1998; 33: 81-91.
45. Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza PL, Bucher HC, Bernasconi E, Sudre P, Leduc D, Yerly S, Perrin LH, Hirschel B: A placebocontrolled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. *AIDS* 1998; 12: F71-77.
46. Rutschmann OT, Opravil M, Iten M, Malinverni R, Vernazza PL, Bucher H, Bernasconi E, Perrin LH, Yerly S, Hirschel B. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. *Antiviral Therapy* 1998; 3 Suppl. 4: 65-67.
47. Shmerling D, Hegyi I, Fischer M, Blattler T, Brandner S, Gotz J, Rulicke T, Flechsig E, Cozzio A, von M.C, Hangartner C, Aguzzi A, Weissmann C. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. *Cell* 1998; 93: 203-214.
48. Vogt PR, Brunner-LaRocca H-P, Carrel T, von Segesser LK, Ruef C, Debatin J, Seifert B, Kiowski W, Turina ML. Cryopreserved arterial allografts in the treatment of major vascular infection: a comparison with conventional surgical techniques. *J Thorac Cardiovasc Surg* 1998; 116: 965-972.
49. Wanke CA, Mayer H, Weber R, Zbinden R, Watson DA, Acheson D. Enteroaggregative *Escherichia coli* as a potential cause of diarrheal disease in adults infected with human immunodeficiency virus. *J Infect Dis* 1998;178:185-190.
50. Weber R, Fuchs KP, Jost J, Nadal D, Opravil M, Ott PM, Perruchoud A, Ruef C, Steffen R, Zbinden R. Antibiotika: Nutzen und Gefahren für Individuum und Gesellschaft (Teil 1). *Schweiz. Aerztezeitung* 1998;79: 2307-2310.
51. Weber R, Pusterla N, Loy M, Lutz H. Fever, leukopenia and thrombocytopenia in a patient with acute Lyme borreliosis was due to coinfection with Human Granulocytic Ehrlichia. [letter] *Clin Infect Dis* 1998; 26: 253-254.

52. Weissmann C, Fischer M, Raeber A, Bueler H, Sailer A, Shmerling D, Rulicke T, Brandner S, Aguzzi A. The use of transgenic mice in the investigation of transmissible spongiform encephalopathies. *Rev Sci Tech* 1998; 17: 278-290.
53. Im Rahmen der Schweiz. HIV-Kohortenstudie (SHCS) oder anderer Forschungsgruppen publiziert
54. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A, Leonard J for the Advanced HIV Disease Ritonavir Study Group. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. *Lancet*. 1998; 351: 543-9.
55. Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P and the Advanced HIV Disease Ritonavir Study Group. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. *AIDS* 1998; 12: 1495-502.
56. Gebhardt M, Rickenbach M, Egger M and the Swiss HIV Cohort Study: Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. *AIDS* 1998; 12: 1195-1201.
57. Kaufmann D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV Cohort Study. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). [letter] *Lancet* 1998; 351: 723-724
58. Kirk O, Mocroft A, Katzenstein TL, Lazzarin A, Antunes F, Francioli P, Brettle RP, Parkin JM, Gonzales-Lahoz J, Lundgren JD for the EuroSIDA Study Group. Changes in use of antiretroviral therapy in regions of Europe over time. *AIDS* 1998; 12: 2031-9.
59. Lorenzi P, Masserey Spicher V, Laubereau B et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. *AIDS* 1998; 12: F241-F247.
60. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio-Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD for the EuroSIDA Study Group. Changing patterns of mortality across Europe in patients infected with HIV-1. *Lancet* 1998; 352: 1725-30.
61. Perneger TV, Yerly S, Perrin L and the Swiss HIV Cohort Study: Transforming laboratory test results to improve clinical outcome predictions in HIV patients. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998; 17: 442-449.
62. Phillips AN, Katlama C, Barton S, Vella S, Blaxhult A, Clotet B, Goebel FD, Hirschel B, Pedersen C, Lundgren JD for the EuroSIDA Study Group. Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998; 17: 239-44.
63. Pichard C, Sudre P, Karsegard V, Yerly S, Slosman DO, Perrin L, Hirschel B and the Swiss HIV Cohort Study. A randomized double-blind controlled study of 6 months oral nutritional supplementation with arginine and ω -3 fatty acids in HIV-infected patients. *AIDS* 1998; 12: 53-63.

64. Rizzardì GP, Morawetz RA, Vicenzi E, Ghezzi S, Poli G, Lazzarin A, Pantaleo G and the Swiss HIV Cohort. CCR2 polymorphism and HIV disease. [letter] *Nat Med* 1998; 4: 252-3.
65. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulaflia D, Galleshaw J, Dezube BJ for the International Pegylated Liposomal Doxorubicin Study Group: Randomised comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. *J Clin Oncol* 1998; 16: 683-691.
66. Yerly S, Perneger TV, Hirschel B, Dubuis O, Matter L, Malinverni R, Furrer H, Perrin L for the Swiss HIV Cohort Study. A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. *Arch Intern Med* 1998; 158: 247-52.